Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade

Approval of the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab by the FDA in 2004 reflected the success of this vascular targeting strategy in extending survival in patients with advanced cancers. However, consistent with previous reports that experimental tumors can grow or rec...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Huang, Jianzhong, Bae, Jae-O, Tsai, Judy P., Kadenhe-Chiweshe, Angela, Papa, Joey, Lee, Alice, Zeng, Shan, Kornfeld, Z. Noah, Ullner, Paivi, Zaghloul, Nibal, Ioffe, Ella, Nandor, Sarah, Burova, Elena, Holash, Jocelyn, Thurston, Gavin, Rudge, John, Yancopoulos, George D., Yamashiro, Darrell J., Kandel, Jessica J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2009
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3160826/
https://ncbi.nlm.nih.gov/pubmed/19082480
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller